Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Incomplete TUR plus IL-2 versus complete TUR plus IL-2 in non-muscle invasive bladder cancer
2010-020397-42Phase 3Active
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Oct 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of aldesleukin in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Amsterdam UMC, location VUmc. Primary endpoint: recurrence-free period after intervention. Started Oct 2010; status: active.
02
Drugs
aldesleukin
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2010-020397-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020397-42.